Your browser doesn't support javascript.
loading
Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule.
Grinkevich, Vera V; Vema, Aparna; Fawkner, Karin; Issaeva, Natalia; Andreotti, Virginia; Dickinson, Eleanor R; Hedström, Elisabeth; Spinnler, Clemens; Inga, Alberto; Larsson, Lars-Gunnar; Karlén, Anders; Wilhelm, Margareta; Barran, Perdita E; Okorokov, Andrei L; Selivanova, Galina; Zawacka-Pankau, Joanna E.
Affiliation
  • Grinkevich VV; Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
  • Vema A; Division of Organic Pharmaceutical Chemistry, Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
  • Fawkner K; Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
  • Issaeva N; Department of Otolaryngology/Head and Neck Surgery, UNC-Chapel Hill, Chapel Hill, NC, United States.
  • Andreotti V; IRCCS Ospedale Policlinico San Martino, Genetics of Rare Cancers, Genoa, Italy.
  • Dickinson ER; Manchester Institute of Biotechnology, The School of Chemistry, The University of Manchester, Manchester, United Kingdom.
  • Hedström E; Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
  • Spinnler C; Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
  • Inga A; Department CIBIO, University of Trento, Trento, Italy.
  • Larsson LG; Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
  • Karlén A; Division of Organic Pharmaceutical Chemistry, Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
  • Wilhelm M; Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
  • Barran PE; Manchester Institute of Biotechnology, The School of Chemistry, The University of Manchester, Manchester, United Kingdom.
  • Okorokov AL; Wolfson Institute for Biomedical Research, University College London, London, United Kingdom.
  • Selivanova G; Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
  • Zawacka-Pankau JE; Department of Medicine, Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden.
Front Mol Biosci ; 9: 823195, 2022.
Article in En | MEDLINE | ID: mdl-35720128
ABSTRACT
Restoration of the p53 tumor suppressor for personalised cancer therapy is a promising treatment strategy. However, several high-affinity MDM2 inhibitors have shown substantial side effects in clinical trials. Thus, elucidation of the molecular mechanisms of action of p53 reactivating molecules with alternative functional principle is of the utmost importance. Here, we report a discovery of a novel allosteric mechanism of p53 reactivation through targeting the p53 N-terminus which promotes inhibition of both p53/MDM2 (murine double minute 2) and p53/MDM4 interactions. Using biochemical assays and molecular docking, we identified the binding site of two p53 reactivating molecules, RITA (reactivation of p53 and induction of tumor cell apoptosis) and protoporphyrin IX (PpIX). Ion mobility-mass spectrometry revealed that the binding of RITA to serine 33 and serine 37 is responsible for inducing the allosteric shift in p53, which shields the MDM2 binding residues of p53 and prevents its interactions with MDM2 and MDM4. Our results point to an alternative mechanism of blocking p53 interaction with MDM2 and MDM4 and may pave the way for the development of novel allosteric inhibitors of p53/MDM2 and p53/MDM4 interactions.
Key words